Knopp Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Knopp Biosciences sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Knopp Biosciences: 12 sponsored US clinical trials, none currently recruiting.

Knopp Biosciences sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Eosinophilic Asthma, with 1 trials.

Top-decile sponsor footprint

Knopp Biosciences ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 2

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939
COMPLETED Phase 2

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
COMPLETED Phase 1

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

NCT01607034
TERMINATED Phase 3

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088
COMPLETED Phase 1

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

NCT01597310
COMPLETED Phase 1

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
COMPLETED Phase 1

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

NCT01511029
COMPLETED Phase 1

Dexpramipexole SAD/MAD Study

NCT01449578
COMPLETED Phase 1

Dexpramipexole Renal PK Study

NCT01424176
COMPLETED Phase 3

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
COMPLETED Phase 2

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

NCT00931944
COMPLETED Phase 2

Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)

NCT00647296

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 4
Phase 3 2

Therapeutic Areas

Eosinophilic Asthma 1
Asthma 1
Healthy Volunteers 1
Amyotrophic Lateral Sclerosis 1

How the Knopp Biosciences early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Eosinophilic Asthma (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Knopp Biosciences: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Knopp Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Knopp BiosciencesAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Knopp Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Knopp Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Knopp Biosciences page

12 registered trials is a research-attention snapshot, not an endorsement of Knopp Biosciences or any single study.

  • None of Knopp Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Eosinophilic Asthma is the condition Knopp Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Eosinophilic Asthma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Knopp Biosciences pipeline card: 12 registered trials from official public datasets.Report a data error.